1
MSc Student, Department of Biology, School of Science, Urmia University, Urmia, Iran
2
Assistant of Professor, Department of Biology, School of Science, Urmia University, Urmia, Iran
Abstract
Background: This study was aimed to evaluate the effect of high and low molecular weight of protein fraction obtained from Lactobacillus casei and paracasei cell wall on K562 cell line.Methods: Bacteria cultured in special medium and incubated in anaerobic condition and washed with PBS (Phosphate buffered saline) and then, sonicated and centrifuged for cell wall separation. Protein precipitation was conducted with trichloroacetc acid (72%) and sodium deoxalate (15%). Then, different concentrations (500, 1000, 2000, 3000 and 4000 µg/ml) of cell wall proteins were prepared in cell culture medium for each bacteria, separately. In-vitro anticancer properties of both bacteria proteins were assayed in 12, 24, 48 and 72 hours with MTT colorimetric method [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] with 10000 cells per well.Findings: The high and low molecular weight proteins of both bacteria inhibit the growth of K562 significantly (P = 0.046).Conclusion: Based on the results, we conclude that high molecular weight of both probiotic bacteria significantly could inhibit the growth of K562 more than the low molecular protein fractions. Also, protein fraction of Lactobacillus paracasei significantly had more anticancer properties than protein fraction of Lactobacillus casei.
Schrezenmeir J, de VM. Probiotics, prebiotics, and synbiotics--approaching a definition. Am J Clin Nutr 2001; 73(2 Suppl): 361S-4S.
de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71(2): 405-11.
Willett W. The search for the causes of breast and colon cancer. Nature 1989; 338(6214): 389-94.
Hashemi M, Kroczak TJ. Apoptosis and autoimmune disease. Current Medicinal Chemistry 2005; 4(4): 429-37.
Schar-Zammaretti P, Dillmann ML, D'Amico N, Affolter M, Ubbink J. Influence of fermentation medium composition on physicochemical surface properties of Lactobacillus acidophilus. Appl Environ Microbiol 2005; 71(12): 8165-73.
Juarez Tomas MS, Ocana VS, Wiese B, Nader-Macias ME. Growth and lactic acid production by vaginal Lactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli. J Med Microbiol 2003; 52(Pt 12): 1117-24.
Bromberg R, Moreno I, Zaganini CL, Delboni RR, Delboni RR. Isolation of bacteriocin-producing lactic acid bacteria from meat and meat products and its spectrum of inhibitory activity. Braz J Microbiol 2004; 35(1-2): 137-44.
Gill HS, Rutherfurd KJ, Prasad J, Gopal PK. Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br J Nutr 2000; 83(2): 167-76.
Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001; 73(2 Suppl): 451S-5S.
Rafter J. The effects of probiotics on colon cancer development. Nutr Res Rev 2004; 17(2): 277-84.
Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370(9584): 342-50.
Ekert H, Jurk IH, Waters KD, Tiedemann K. Prophylactic co-trimoxazole and lactobacilli preparation in neutropenic patients. Med Pediatr Oncol 1980; 8(1): 47-51.
Choi SS, Kim Y, Han KS, You S, Oh S, Kim SH. Effects of Lactobacillus strains on cancer cell proliferation and oxidative stress in vitro. Lett Appl Microbiol 2006; 42(5): 452-8.
Kabiri F, Nejati V, Tukmechi A, Delirezh N, Nikbakhsh P. Inhibitiory properties of cytoplasmic extract of Lactobacilli isolated from common carp intestine on human chronic myelocytic leukemia K562 cell line: an in vitro study. Tehran Univ Med J 2011; 68(12): 691-8. [In Persian].
Azizpour K. Biochemical characterization of lactic acid bacteria isolated from rainbow trout (Oncorhynchus mykiss) of West Azarbaijn, Iran. Res J Biol Sci 2009; 4(3): 324-6.
Sanchez B, Schmitter JM, Urdaci MC. Identification of novel proteins secreted by Lactobacillus rhamnosus GG grown in de Mann-Rogosa-Sharpe broth. Lett Appl Microbiol 2009; 48(5): 618-22.
Kruger NJ. The Bradford method for protein quantitation. In: Walker JM, editor. The protein protocols handbook. Totowa, NJ: Humana Press; 1996. p. 11-5.
Fisher L. Experimental and technique in column of gel filterasion choromatography. In: Fisher L, Editor. Gel filterasion choromatography. 2nd ed. Philadelphia, PA: Elsevier Publication; 1980. p. 81-137.
Tsai YT, Cheng PC, Fan CK, Pan TM. Time-dependent persistence of enhanced immune response by a potential probiotic strain Lactobacillus paracasei subsp. paracasei NTU 101. Int J Food Microbiol 2008; 128(2): 219-25.
Biffi A, Coradini D, Larsen R, Riva L, Di FG. Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line. Nutr Cancer 1997; 28(1): 93-9.
Fichera GA, Giese G. Non-immunologically-mediated cytotoxicity of Lactobacillus casei and its derivative peptidoglycan against tumor cell lines. Cancer Lett 1994; 85(1): 93-103.
Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol 2008; 10(7): 1442-52.
Roy MK, Kuwabara Y, Hara K, Watanabe Y, Tamai Y. Peptides from the N-terminal end of bovine lactoferrin induce apoptosis in human leukemic (HL-60) cells. J Dairy Sci 2002; 85(9): 2065-74.
Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006; 25(2): 304-9.
Singhal N, Bapsy PP, Babu KG, George J. Chronic myeloid leukemia. J Assoc Physicians India 2004; 52: 410-6.
Rosca A, Arion C, Colita A, Nedelcu L, Scirneciu C, Andreescu O, et al. Chronic myelogenous leukemia prognosis and evolution. Bulletin of the Transilvania University of Brasov 2009; 2(51): 97-104.
Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006; 81(7): 973-88.
Valent P. Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics 2007; 1(4): 433-48.
Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009; 453-60.
Bagheri, M., & Mohammadzadeh, M. (2014). In-Vitro Growth Inhibition of K562 Cell Line with Cell Wall Protein Fraction of Lactobacillus Casei and Lactobacillus Paracasei. Journal of Isfahan Medical School, 32(293), 1081-1092.
MLA
Marzieh Bagheri; Mehdi Mohammadzadeh. "In-Vitro Growth Inhibition of K562 Cell Line with Cell Wall Protein Fraction of Lactobacillus Casei and Lactobacillus Paracasei", Journal of Isfahan Medical School, 32, 293, 2014, 1081-1092.
HARVARD
Bagheri, M., Mohammadzadeh, M. (2014). 'In-Vitro Growth Inhibition of K562 Cell Line with Cell Wall Protein Fraction of Lactobacillus Casei and Lactobacillus Paracasei', Journal of Isfahan Medical School, 32(293), pp. 1081-1092.
VANCOUVER
Bagheri, M., Mohammadzadeh, M. In-Vitro Growth Inhibition of K562 Cell Line with Cell Wall Protein Fraction of Lactobacillus Casei and Lactobacillus Paracasei. Journal of Isfahan Medical School, 2014; 32(293): 1081-1092.
)